Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
These exploratory analyses support the efficacy and tolerability of avelumab 1L maintenance in patients aged ≥65 years with la/mUC that has not progressed following chemotherapy, suggesting that older age should not solely prevent a patient from receiving avelumab 1L maintenance.
Authors
- Justin Hoffman (ORCID: https://orcid.org/0000-0001-7342-5067)
- Yoshihiko Tomita (ORCID: https://orcid.org/0000-0002-7465-9591)
- T. Powles
- Juliane Manitz (ORCID: https://orcid.org/0000-0003-0459-1453)
- J. Bellmunt
- Shilpa Gupta (ORCID: https://orcid.org/0000-0002-8775-503X)
- Norihiko Tsuchiya (ORCID: https://orcid.org/0000-0003-4242-2618)
- S.S. Sridhar
- P. Grivas
- Howard Gurney (ORCID: https://orcid.org/0000-0003-0217-5261)
- A. di Pietro
- Daniel Peter Petrylak (ORCID: https://orcid.org/0000-0001-6165-5797)
- Miguel Á. Climent Durán (ORCID: https://orcid.org/0000-0001-7523-0212)
- Karin Tyroller
- S.H. Park
- N. Jacob
Institutions
- Yamagata University (JP)
- St Bartholomew's Hospital (GB)
- Cleveland Clinic (US)
- Harvard University (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Queen Mary University of London (GB)
- University of Toronto (CA)
- University of Washington (US)
- Samsung Medical Center (KR)
- Princess Margaret Cancer Centre (CA)
- Yale University (US)
- Fred Hutch Cancer Center (US)
- Fundación Instituto Valenciano de Oncología (ES)
- Merck Serono S.A. (Switzerland) (CH)
- Dana-Farber Cancer Institute (US)
- Pfizer (Italy) (IT)
- Seattle University (US)
- Niigata University (JP)
- Sungkyunkwan University (KR)
- Merck Serono S.p.A. (Italy) (IT)
- Macquarie University (AU)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104506
- Citations
- 5
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.03